| review article | Q7318358 |
| scholarly article | Q13442814 |
| P356 | DOI | 10.1007/S11883-008-0003-5 |
| P698 | PubMed publication ID | 18366980 |
| P2093 | author name string | J David Orr | |
| P2860 | cites work | The effect of cholesterol-lowering agents on hepatic and plasma cholesterol in Niemann-Pick disease type C. | Q42289261 |
| Neurological and neurodegenerative alterations in a transgenic mouse model expressing human alpha-synuclein under oligodendrocyte promoter: implications for multiple system atrophy. | Q42486578 | ||
| Dietary copper and high saturated and trans fat intakes associated with cognitive decline | Q44028658 | ||
| Impaired ABCA1-dependent lipid efflux and hypoalphalipoproteinemia in human Niemann-Pick type C disease | Q44482162 | ||
| Prophylactic but not delayed administration of simvastatin protects against long-lasting cognitive and morphological consequences of neonatal hypoxic-ischemic brain injury, reduces interleukin-1beta and tumor necrosis factor-alpha mRNA induction, an | Q44493582 | ||
| 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors protect cortical neurons from excitotoxicity. | Q44681111 | ||
| Early Abeta accumulation and progressive synaptic loss, gliosis, and tangle formation in AD brain | Q44810166 | ||
| Oral simvastatin treatment in relapsing-remitting multiple sclerosis | Q44897670 | ||
| Heart disease and stroke statistics--2006 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee | Q45002081 | ||
| Attenuation of acute inflammatory response by atorvastatin after spinal cord injury in rats | Q45191278 | ||
| C-reactive protein levels and outcomes after statin therapy | Q45213511 | ||
| 3-Hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors attenuate beta-amyloid-induced microglial inflammatory responses. | Q45221796 | ||
| Statins, cholesterol, Co-enzyme Q10, and Parkinson's disease | Q45285170 | ||
| Simvastatin reverses the downregulation of dopamine D1 and D2 receptor expression in the prefrontal cortex of 6-hydroxydopamine-induced Parkinsonian rats | Q46504693 | ||
| Neuronal nitric oxide synthase mediates statin-induced restoration of vasa nervorum and reversal of diabetic neuropathy | Q46570634 | ||
| Effects of acute treatment with pravastatin on cerebral vasospasm, autoregulation, and delayed ischemic deficits after aneurysmal subarachnoid hemorrhage: a phase II randomized placebo-controlled trial | Q46622603 | ||
| Lovastatin reduces neuronal cell death in hippocampal CA1 subfield after pilocarpine-induced status epilepticus: preliminary results | Q46885065 | ||
| The role of lipid-lowering drugs in cognitive function: a meta-analysis of observational studies | Q47811906 | ||
| Galbraith Award: simvastatin attenuates experimental cerebral vasospasm and ameliorates serum markers of neuronal and endothelial injury in patients after subarachnoid hemorrhage: a dose-response effect dependent on endothelial nitric oxide synthase | Q48337350 | ||
| C-reactive protein as a predictor of incident ischemic stroke among patients with preexisting cardiovascular disease | Q48513398 | ||
| Statin use and the risk of Alzheimer's disease: the MIRAGE study. | Q50735085 | ||
| Presence of an APOE4 allele results in significantly earlier onset of Parkinson's disease and a higher risk with dementia. | Q51926699 | ||
| Early inflammation and dementia: a 25-year follow-up of the Honolulu-Asia Aging Study. | Q53250180 | ||
| Lovastatin therapy for X-linked adrenoleukodystrophy: clinical and biochemical observations on 12 patients | Q73933188 | ||
| Meta-analysis of cardiovascular outcomes trials comparing intensive versus moderate statin therapy | Q80020360 | ||
| High-dose atorvastatin after stroke or transient ischemic attack | Q80088259 | ||
| 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors reduce the risk of perioperative stroke and mortality after carotid endarterectomy | Q81454101 | ||
| Markers of inflammation and cardiovascular disease: application to clinical and public health practice: A statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association | Q22241929 | ||
| Pleiotropic effects of statins | Q24647863 | ||
| Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins | Q29547856 | ||
| Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines | Q29619614 | ||
| Brain cholesterol: long secret life behind a barrier. | Q33975527 | ||
| Effects of cholesterol-lowering with simvastatin on stroke and other major vascular events in 20536 people with cerebrovascular disease or other high-risk conditions | Q33976631 | ||
| Atorvastatin for the treatment of mild to moderate Alzheimer disease: preliminary results. | Q34417321 | ||
| Immunomodulatory synergy by combination of atorvastatin and glatiramer acetate in treatment of CNS autoimmunity | Q34448370 | ||
| Simvastatin strongly reduces levels of Alzheimer's disease beta -amyloid peptides Abeta 42 and Abeta 40 in vitro and in vivo | Q34514599 | ||
| Neuroprotection in Parkinson disease: mysteries, myths, and misconceptions | Q35634218 | ||
| Statins in stroke prevention and carotid atherosclerosis: systematic review and up-to-date meta-analysis | Q35932795 | ||
| Statins--a cure-all for the brain? | Q36085649 | ||
| Isoprenoids determine Th1/Th2 fate in pathogenic T cells, providing a mechanism of modulation of autoimmunity by atorvastatin | Q36228304 | ||
| Cholesterol in Alzheimer's disease | Q36317585 | ||
| The dynamics of statins: from event prevention to neuroprotection | Q36367291 | ||
| HMG-CoA reductase inhibitors: effects on chronic subacute inflammation and onset of atherosclerosis induced by dietary cholesterol | Q36407494 | ||
| Final conclusions and recommendations of the National Lipid Association Statin Safety Assessment Task Force. | Q36438054 | ||
| Statins in the treatment of central nervous system autoimmune disease | Q36543684 | ||
| Lipid-lowering agent use at ischemic stroke onset is associated with decreased mortality | Q39724657 | ||
| Effects of atorvastatin on stroke in patients with unstable angina or non-Q-wave myocardial infarction: a Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) substudy | Q40632159 | ||
| P433 | issue | 1 | |
| P304 | page(s) | 11-18 | |
| P577 | publication date | 2008-02-01 | |
| P1433 | published in | Current Atherosclerosis Reports | Q20821076 |
| P1476 | title | Statins in the spectrum of neurologic disease | |
| P478 | volume | 10 |
| Q35087574 | Cholesterol-independent neuroprotective and neurotoxic activities of statins: perspectives for statin use in Alzheimer disease and other age-related neurodegenerative disorders |
| Q41995769 | Increased membrane cholesterol might render mature hippocampal neurons more susceptible to beta-amyloid-induced calpain activation and tau toxicity |
| Q37508584 | Neuronal nicotinic receptors as novel targets for inflammation and neuroprotection: mechanistic considerations and clinical relevance |
| Q38140727 | New strategies in the management of Guillain-Barré syndrome. |
| Q33665461 | Rosuvastatin induces delayed preconditioning against L-glutamate excitotoxicity in cultured cortical neurons |
| Q34015831 | Statins and neuroprotection: a prescription to move the field forward |
| Q38162657 | Statins more than cholesterol lowering agents in Alzheimer disease: their pleiotropic functions as potential therapeutic targets. |
Search more.